Fraser Eye Care Center — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$117,402	13
2023	Research	$10,350	6
2022	Research	$8,132	5
2021	Research	$10,658	4
2020	Research	$8,565	43
2019	Research	$106,565	31

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $123,702 75 payments
Oyster Point Pharma, Inc. $83,631 10 payments
AbbVie, Inc. $52,253 14 payments
Alcon Research LLC $2,086 3 payments

Studies the money was for Research payments · program years 2019–2025

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $108,702 47 payments
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $70,097 7 payments
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $17,687 10 payments
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) $13,534 3 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $13,523 1 payment
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension $11,025 1 payment
A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $9,337 1 payment
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $9,223 1 payment
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patient with Open Angle Glaucoma or Ocular Hypertension $2,361 9 payments
Verona study to understand surgeon impact $2,085 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.